TickerTalks
Browse all tickers →
TickerTalks›$ALKS
ALALKS

Alkermes plc

$ALKS·$7.5B·Biotechnology·Healthcare
$44.57-0.8%YTD+60.4%1Y+44.0%
Mentions · last 7 days
2026-06-05: 0 posts2026-06-06: 2 posts2026-06-07: 3 posts2026-06-08: 9 posts2026-06-09: 10 posts2026-06-10: 3 posts2026-06-11: 8 posts35+30%
Price updated 14m ago·X counts updated 21h ago
ALALKS
Alkermes plc$ALKS
$44.57-0.78%35 posts+30%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $ALKS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventAcceleratingAI verdict · as of 2026-06-12

The move is getting stronger, with heavier trading behind it.

Alkermes printed positive Phase 3 REVITALYZ data and is pushing into orexin Phase 3 — but officers sold $1.7M into the post-data run

Alkermes is a commercial-stage CNS biotech that just released positive topline Phase 3 REVITALYZ data on May 12 (driving the post-Avadel-integration thesis forward) and is preparing for the next CEO transition while alixorexton enters Phase 3 in orexin biology. The fundamental case is real — revenue reaccelerated to 28% in Q1, the EPS print beat by 30%, and the franchise has multiple commercial and clinical levers — but officers Hopkinson, Parisi, and Gaffin filed combined sales of roughly $1.7M into the post-data run. Q1 revenue grew 28% YoY to $393M with operating margin 12.3% and EPS at -$0.40 against -$0.57 expected — a 30% beat on a small base; trailing P/E is 49, price-to-sales 4.8, EV/EBITDA 32, return on capital 3.9%, return on equity 8.8%, debt-to-equity 0.90; 2026 consensus revenue is $1.81B with EPS at -$0.40 turning to positive $0.54 in 2027. The stock sits 96% of the way up its 52-week range, up 44% in twelve months and 60% year-to-date.

What to watch: Alixorexton Phase 3 enrollment cadence and any updated readout timeline; July 28 print for the first quarterly update on Avadel integration and CEO-transition details; further insider Form 4 activity at $44+, where another Hopkinson-or-Parisi-scale block would extend the cluster signal; competitor orexin commentary from Takeda and Roche.

On the calendar: 2026-07-28 — Q2 2026 earnings

no sentiment data

Read the AI verdict + X sentiment for $ALKS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Alkermes plc is an Irish-headquartered biopharmaceutical firm, established in 1987, focused on the discovery, development, and commercialization of innovative pharmaceutical treatments. These efforts are directed at fulfilling critical unmet medical needs for patients across a range of therapeutic areas, both domestically and internationally. Its current portfolio of marketed products features ARISTADA for schizophrenia; VIVITROL, targeting alcohol dependence and preventing opioid dependence; and several medications for schizophrenia and bipolar I disorder, including RISPERDAL CONSTA, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA. Furthermore, VUMERITY is available for managing relapsing forms of multiple sclerosis in adults, encompassing clinically isolated syndrome, relapsing-remitting, and active secondary progressive diseases. The company is also actively developing new drug candidates, such as LYBALVI, an oral atypical antipsychotic for adults with schizophrenia and bipolar I disorder, and nemvaleukin alfa, an engineered fusion protein designed to amplify tumor-killing immune cells while bypassing the activation of immunosuppressive cells. Alkermes maintains key strategic collaboration agreements, primarily with various entities under the Janssen Pharmaceutica umbrella.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ALKS.

Biotechnology · Healthcare

GLP-1 obesity pipeline competition and clinical binary events are the twin forces bifurcating biotech — ALT and VKTX carry high risk/reward ratios in the obesity race while IBRX's bladder/pancreatic immunotherapy catalysts define the oncology binary calendar. Gene editing (CRSP, BEAM, NTLA) is entering commercial maturation with Casgevy revenue scaling.

See how Biotechnology shapes $ALKS

  • Where the industry is in its cycle and the catalysts moving it now
  • What this means specifically for $ALKS's next move
  • Peer-basket or ETF benchmark you can use to gut-check the read
Free, forever. No credit card.

Top industry ETF

$IBBiShares Biotechnology ETF
+0.5%YTD
+33.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
48.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
3.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
12.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
8.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
86.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.9Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 5, 2026$-0.40$-0.57+29.8%
Q4 2025Feb 25, 2026$0.34$0.43-20.9%
Q3 2025Oct 28, 2025$0.49$0.42+16.7%
Q2 2025Jul 29, 2025$0.52$0.41+26.8%
Next earningsTue, Jul 28·consensus EPS $-0.04

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$392.9M+28.2%84.3%-12.3%$-0.40$-169.8M
Q4 FY25$384.5M-10.6%88.0%15.1%$0.30$170.1M
Q3 FY25$394.2M+4.2%86.9%22.6%$0.50$84.4M
Q2 FY25$390.7M-2.1%87.3%23.8%$0.53$137.2M

Forward consensus

5-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.8B$1.8B – $1.8B-$0.40-$0.61 – -$0.3112
FY27$1.9B$1.8B – $1.9B$0.54-$0.31 – $1.6812
FY28$2.1B$2.1B – $2.1B$1.27-$0.82 – $3.4313
FY29$2.3B$2.3B – $2.4B$2.21$2.13 – $2.3612
FY30$2.6B$2.5B – $2.8B$3.35$3.23 – $3.586

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.96%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+22.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+41.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 154.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.335-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Know if $ALKS is setting up — or just chopping

  • Volume multiple vs 30-day baseline — catch unusual interest before the move
  • Position vs 50d & 200d MAs and 52-week range — trend direction at a glance
  • Float bucket, beta, and active-offering flags — what kind of stock you're trading
Free, forever. No credit card.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 4Gaffin David JosephEVP, CLO, Alkermes, Inc.2.0K sh$88KSellJun 1Craig C. HopkinsonEVP R&D, Chief Medical Officer9.0K sh$375KSellMay 29Parisi Samuel JosephVP, Finance (Interim PAO)16.2K sh$687KSellMay 4Gaffin David JosephEVP, CLO, Alkermes, Inc.2.0K sh$68K
+ 26 other (10 exempts · 8 inkinds · 8 awards) in window

See when $ALKS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeMay 208-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

At Alkermes plc's (ALKS) 2026 Annual General Meeting on May 20, 2026, shareholders approved an amendment to the 2018 Stock Option and Incentive Plan increasing ordinary shares authorized for issuance by 5,900,000 shares, as described in the definitive proxy filed April 6, 2026. The filing also covers other director/officer items under Item 5.02 (details cut off) and Item 5.07 annual meeting voting results. The 5.9 million share authorization increase is a routine but moderately dilutive equity compensation action, signaling continued broad equity award activity at the company.

8-KPress release / Reg FDMay 128-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Alkermes plc (ALKS) announced positive topline results from REVITALYZ, a Phase 3, double-blind, placebo-controlled, randomized withdrawal, multicenter study evaluating an investigational use of an ALKS compound (specific drug name cut off in excerpt), disclosed via press release (Exhibit 99.1) and Reg FD disclosure on May 12, 2026. No p-value, effect size, or primary endpoint detail is reproduced in the body excerpt; those are in the exhibit. Positive Phase 3 topline data is a highly material clinical catalyst for ALKS that could expand the label and commercial addressable market for the compound involved.

8-KOfficer or director changeFeb 258-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-KAgreement terminatedFeb 128-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.01: Acquisition completed · Item 2.03: Material debt obligation · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDJan 128-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDJan 68-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
+ 15 other (5 13Gs · 3 proxys · 3 earnings 8-Ks · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Healthcare ETFs: From Broad Exposure to Big Breakthroughsetftrends.com·2d agoAlkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nearsmarketbeat.com·2d agoAlkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·2d agoAlkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tells Investorsgurufocus.com·3d agoHealthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotechfool.com·7d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALLO$NVO$AURA$HUMA$IBRX$ALT$RXRX$DARE
Voices on X · last 7 days

No standout posts about $ALKS on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport